SPOTLIGHT: Talecris may be sold


Almost a year after filing plans for a $1 billion IPO for Talecris Biotherapeutics, Cerberus and partner Ampersand Ventures may instead pursue a sale of the blood plasma product business. And Australia's CSL may be in the running. The blood plasma product business has been rapidly consolidating. Talecris said last year that three companies controlled 82 percent of the U.S. market. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.